Therapeutic Asset Ratings
3,272 results matching 1 filter
91,583 assets · 7,906 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Dabrafenib
Glioblastoma
National Cancer Institute (NCI)
P4
B
(56)
Capecitabine
Fallopian Tube Cancer
National Cancer Institute (NCI)
P3
B
(56)
DIPHENHYDRAMINE
Cervical Cancer
National Cancer Institute (NCI)
P3
B
(56)
Belinostat
Neuroendocrine Carcinoma
National Cancer Institute (NCI)
P2
B
(56)
cd22 car-transduced t cells
Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
P2
B
(56)
Dasatinib
Ovarian Carcinoma
National Cancer Institute (NCI)
P2
B
(56)
Fludarabine
Refractory Malignant Neoplasm
National Cancer Institute (NCI)
P2
B
(56)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Glioblastoma
National Cancer Institute (NCI)
P2
B
(56)
Ipilimumab
Lymphoma
National Cancer Institute (NCI)
P2
B
(56)
Selinexor
Glioblastoma
National Cancer Institute (NCI)
P2
B
(56)
Decitabine
Hodgkins Lymphoma
National Cancer Institute (NCI)
P2/3
B
(56)
Alpelisib
Metastatic Malignant Neoplasm
National Cancer Institute (NCI)
P2
CCC
(55)
Bet Bromodomain Inhibitor Zen-3694
Metastatic Malignant Neoplasm
National Cancer Institute (NCI)
P2
CCC
(55)
Binimetinib
Metastatic Malignant Neoplasm
National Cancer Institute (NCI)
P2
CCC
(55)
ca-4948
Myelodysplastic Syndrome
National Cancer Institute (NCI)
P2
CCC
(55)
Ceralasertib
Metastatic Malignant Neoplasm
National Cancer Institute (NCI)
P2
CCC
(55)
CIS-DIAMMINEDICHLOROPLATINUM II
Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
P2
CCC
(55)
Copanlisib
Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
P2
CCC
(55)
Decitabine
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
P2
CCC
(55)
DENTALFLUORO
Metastatic Prostate Carcinoma
National Cancer Institute (NCI)
P2
CCC
(55)
Duvelisib
Enteropathy-Associated T-Cell Lymphoma
National Cancer Institute (NCI)
P2
CCC
(55)
Duvelisib
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
National Cancer Institute (NCI)
P2
CCC
(55)
Fludarabine
Rhabdomyosarcoma
National Cancer Institute (NCI)
P2
CCC
(55)
FLUDEOXYGLUCOSE
Urinary Bladder Carcinoma
National Cancer Institute (NCI)
P2
CCC
(55)
FLUDEOXYGLUCOSE
Cholangiocarcinoma
National Cancer Institute (NCI)
P2
CCC
(55)
Showing 901 to 925 of 3,272 assets
Previous
Page 37 of 131
Next